Companies Karuna Therapeutics
Karuna Therapeutics (KRTX): executive pay, fiscal 2022
Free brief. Every figure links to the company’s own filing.
Karuna Therapeutics no longer files a proxy statement; its last pay data is FY2022.
CEO vs. named peers69th pct.Of 18 peer CEOs
CEO pay, last three years
- $8,902,241FY2020
- $13,136,960FY2021
- $11,224,103FY2022
CEO total pay was $11,224,103 in fiscal 2022, down from $13,136,960 in fiscal 2021.
FY2022: salary $700,000 · bonus $0 · stock awards $0 · option awards $9,905,953
Frequently asked questions
Who was the highest-paid executive at Karuna Therapeutics in fiscal 2022?
As disclosed, Steven Paul (President and Chief Executive Officer) was the highest-paid executive at Karuna Therapeutics in fiscal 2022, with total compensation of $11,224,103.
How does Karuna Therapeutics's chief executive pay compare to its disclosed peer group?
As disclosed, Steven Paul's total compensation ranked at the 69th percentile of Karuna Therapeutics's disclosed peer group.
What is Karuna Therapeutics's CEO-to-median employee pay ratio?
As disclosed, Karuna Therapeutics's CEO-to-median employee pay ratio was 27:1.
How did shareholders vote on Karuna Therapeutics's executive compensation?
As disclosed, 65.16% of shareholders supported Karuna Therapeutics's executive compensation in the latest say-on-pay vote.
How much does Karuna Therapeutics spend in total on board compensation for fiscal 2022?
As disclosed, Karuna Therapeutics reported total board compensation of $401,292 for fiscal 2022.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Steven Paul | $700,000 | $0 | $0 | $9,905,953 | $609,000 | $0 | $9,150 | $11,224,103 |
| President and Chief Executive Officer | ||||||||
| Andrew Miller | 500,000 | 0 | 0 | 4,939,490 | 326,250 | 0 | 9,150 | 5,774,890 |
| Chief Operating Officer | ||||||||
| Stephen Brannan | 470,000 | 0 | 0 | 3,661,629 | 272,600 | 0 | 9,150 | 4,413,379 |
| Chief Medical Officer | ||||||||
| Troy Ignelzi | 460,000 | 0 | 0 | 3,270,515 | 266,800 | 0 | 9,150 | 4,006,465 |
| Chief Financial Officer | ||||||||
| Charmaine Lykins | 475,000 | 0 | 0 | 0 | 275,500 | 0 | 9,150 | 759,650 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2022 total | FY2021 total | FY2020 total | Δ FY2021→2022 |
|---|---|---|---|---|
| Steven Paul | $11,224,103 | $13,136,960 | $8,902,241 | ↓ −1,912,857 |
| Andrew Miller | 5,774,890 | 5,722,168 | 4,662,146 | ↑ +52,722 |
| Stephen Brannan | 4,413,379 | 4,523,798 | 3,492,833 | ↓ −110,419 |
| Troy Ignelzi | 4,006,465 | 4,513,517 | 3,751,661 | ↓ −507,052 |
| Charmaine Lykins | 759,650 | 5,832,673 | — | ↓ −5,073,023 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy is performance-based, focusing on aligning the financial interests of executive officers with those of shareholders by placing a substantial portion of total compensation 'at risk' through variable pay tied to pre-set, objective financial or operating goals and stock price appreciation. The program aims to link pay to the achievement of corporate and strategic goals, promote an ownership culture through equity, and provide market-competitive compensation to attract and retain talent.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2022
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Troy Ignelzi | OPTION | 2022-02-16 | — | — | 48,500 | — | $3,270,515 |
| Stephen Brannan | OPTION | 2022-02-16 | — | — | 54,300 | — | 3,661,629 |
| Andrew Miller | OPTION | 2022-02-16 | — | — | 73,250 | — | 4,939,490 |
| Steven Paul | OPTION | 2022-02-16 | — | — | 146,900 | — | 9,905,953 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Troy Ignelzi | $0 | $0 | $3,270,515 | 0.0% |
| Stephen Brannan | 0 | 0 | 3,661,629 | 0.0% |
| Andrew Miller | 0 | 0 | 4,939,490 | 0.0% |
| Steven Paul | 0 | 0 | 9,905,953 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2022
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Stephen Brannan | Option | 11,362 | 9.2 | — |
| Stephen Brannan | Option | 15,625 | 99.72 | — |
| Troy Ignelzi | Option | 17,187 | 99.72 | — |
| Andrew Miller | Option | 21,875 | 99.72 | — |
| Stephen Brannan | Option | 28,884 | 131.64 | — |
| Troy Ignelzi | Option | 29,053 | 131.64 | — |
| Troy Ignelzi | Option | 34,224 | 9.2 | — |
| Andrew Miller | Option | 37,631 | 131.64 | — |
| Steven Paul | Option | 43,750 | 99.72 | — |
| Troy Ignelzi | Option | 48,500 | 111.97 | — |
| Stephen Brannan | Option | 54,300 | 111.97 | — |
| Charmaine Lykins | Option | 56,250 | 125.52 | — |
| Andrew Miller | Option | 73,250 | 111.97 | — |
| Steven Paul | Option | 91,040 | 131.64 | — |
| Steven Paul | Option | 146,900 | 111.97 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christopher J. CoughlinIndependent · Board Chair · Audit (Chair) · Compensation | $89,042 | $0 | $284,104 | — | $0 | $373,145 |
| Laurie OlsonIndependent · Audit · Nominating and Corporate Governance (Chair) | 61,000 | 0 | 284,104 | — | 0 | 345,104 |
| Atul Pande, M.DIndependent · Compensation (Chair) · Nominating and Corporate Governance | 60,500 | 0 | 284,104 | — | 0 | 344,604 |
| James Healy, M.D., Ph.DIndependent · Audit | 52,000 | 0 | 284,104 | — | 0 | 336,104 |
| Denice TorresIndependent · Compensation | 49,250 | 0 | 284,104 | — | 0 | 333,354 |
| David Wheadon, M.DIndependent · Nominating and Corporate Governance | 47,000 | 0 | 284,104 | — | 0 | 331,104 |
| Jeffrey Jonas, M.DNot independent | 42,500 | 0 | 284,104 | — | 0 | 326,604 |
| Steven Paul, M.DEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Bill MeuryEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2022 |
|---|---|
| Cash retainers and fees | $401,292 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $401,292 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Karuna Therapeutics as a peer
Companies that benchmark against KRTX
1 company names KRTX as a compensation peer
The list of companies that name KRTX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2022
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
BTAI BioXcel Therapeutics, Inc.PRTA Prothena Corporation plcBHVN Biohaven Pharmaceutical Holding Company Ltd.ACAD Acadia Pharmaceuticals Inc.CERE Cerevel Therapeutics Holdings, Inc.AXSM Axsome Therapeutics, Inc.RYTM Rhythm Pharmaceuticals, Inc.APLS Apellis Pharmaceuticals, Inc.ITCI Intra-Cellular Therapies, Inc.ALEC Alector, Inc.ALLK Allakos Inc.ARVN Arvinas, Inc. Cortexyme, Inc.DNLI Denali Therapeutics Inc.KOD Kodiak Sciences Inc.MRTX Mirati Therapeutics, Inc.SAGE Sage Therapeutics, Inc.TGTX TG Therapeutics, Inc.
Peer reciprocity
The companies Karuna Therapeutics names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | TG Therapeutics, Inc. | 2025 | Michael Weiss | $875,000 | $23,550,000 | $0 | $1,146,250 | $25,571,250 |
| 2 | Rhythm Pharmaceuticals, Inc. | 2025 | David Meeker | 807,692 | 8,274,785 | 7,688,560 | 759,488 | 17,544,525 |
| 3 | Biohaven Pharmaceutical Holding Company Ltd. | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 4 | Mirati Therapeutics, Inc. | 2022 | David Meek | 749,423 | 6,043,885 | 4,233,427 | 438,985 | 11,937,371 |
| 5 | Cerevel Therapeutics Holdings, Inc. | 2022 | N. Anthony Coles | 642,735 | 0 | 10,085,985 | 496,706 | 11,225,426 |
| 6 | Karuna Therapeutics | 2022 | Steven Paul | 700,000 | 0 | 9,905,953 | 609,000 | 11,224,103 |
| 7 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 9 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 10 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 11 | Sage Therapeutics, Inc. | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 12 | Arvinas, Inc. | 2025 | John Houston | 706,236 | 2,685,840 | 2,671,051 | 457,000 | 6,534,127 |
| 13 | Allakos Inc. | 2023 | Robert Alexander | 805,460 | 2,171,340 | 2,623,519 | 684,641 | 6,299,426 |
| 14 | Prothena Corporation plc | 2025 | Gene Kinney | 692,973 | 961,800 | 3,809,738 | 415,784 | 5,896,045 |
| 15 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| 16 | Kodiak Sciences Inc. | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
| 17 | Alector, Inc. | 2025 | Arnon Rosenthal | 678,100 | 422,876 | 558,216 | 325,488 | 1,995,018 |
| — | BioXcel Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Karuna Therapeutics | 145% | Option 100 | not disclosed | Aon |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alector, Inc. | 80% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Allakos Inc. | not disclosed | Options 55 · RSU 45 | No | Compensia |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arvinas, Inc. | 108% | Options 50 · RSU 50 | not disclosed | Aon (Aon's Human Capital Solutions practice, a division of Aon plc) |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Biohaven Pharmaceutical Holding Company Ltd. | not disclosed | not disclosed | not disclosed | Aon |
| BioXcel Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Radford, a part of Aon plc |
| Cerevel Therapeutics Holdings, Inc. | 128.8% | Options 100 | not disclosed | Pay Governance LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Kodiak Sciences Inc. | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Mirati Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon Human Capital Solutions and Alpine Rewards |
| Prothena Corporation plc | 100% | not disclosed | not disclosed | Pay Governance LLC |
| Rhythm Pharmaceuticals, Inc. | 120% | Options 50 · RSU 50 | No | Pay Governance |
| Sage Therapeutics, Inc. | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2023 | 2023-06-20 | 20,307,726 | 10,859,879 | 413,451 | 65.16% | Passed |
| 2022 | 2022-06-15 | 21,124,063 | 5,639,878 | 414,027 | 78.93% | Passed |
| 2020 | 2020-06-15 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2023 | 2023-06-20 | 65.16%a |
| 2022 | 2022-06-15 | 78.93%b |
| 2020 | 2020-06-15 | —c |
a. Approved under the standard stated in the filing — “As a result, such "broker non-votes" and abstentions will have no effect on the voting on Proposal 2.”.
b. Approved under the standard stated in the filing — “As a result, such broker non-votes and abstentions will have no effect on the voting on Proposal 2.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 27 : 1 |
|---|---|
| CEO total compensation | $11,224,103 |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 7,696 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 4,496 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 1,744 | 174 | 303,055 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 3,256 | 173 | 563,158 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,245 | 180 | 404,280 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 808 | 179 | 144,551 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 265 | 177 | 46,942 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 401 | 176 | 70,452 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 1,281 | 174 | 223,035 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 99 | 204 | 20,214 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 3,969 | 203 | 804,675 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,116 | 202 | 426,861 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 1,565 | 200 | 313,172 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 10,000 | 132 | 1,316,400 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,251 | 204 | 458,754 | Common | Form 4 ↗ |
| Bill Meury | Director | 2023-12-28 | D | 8,694 | 316 | 2,749,912 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2023-12-28 | D | 3,828 | 316 | 1,210,796 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 9,696 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 5,304 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 15,000 | 317 | 4,752,150 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 9,696 | 112 | 1,085,661 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 5,304 | 132 | 698,219 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 818 | 317 | 258,946 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 4,182 | 316 | 1,321,721 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 5,000 | 112 | 559,850 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-09 | D | 1,046 | 317 | 331,728 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-09 | D | 1,011 | 317 | 320,629 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-09 | D | 804 | 317 | 254,981 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-13 | A | 15,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-02-13 | A | 38,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | D | 278 | 318 | 88,404 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 27,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 4,008 | 100 | 399,678 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 27,510 | 7 | 199,998 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-29 | A | 47,378 | 315 | 14,932,598 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2024-03-08 | — | 1,791 | — | — | 1 insider, 1 accrual row | ||
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 3,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 100 | 319 | 31,896 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 4,900 | 318 | 1,559,817 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 1,791 | 112 | 200,538 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 3,209 | 132 | 422,433 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 17,350 | 143 | 2,476,539 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 37,813 | 218 | 8,244,368 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 12,837 | 198 | 2,546,347 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 50,000 | 230 | 11,514,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,362 | 321 | 2,040,930 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 4,677 | 325 | 1,517,920 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,487 | 330 | 2,140,710 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 36,117 | 330 | 11,918,610 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 22,800 | 143 | 3,254,472 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 146,900 | 218 | 32,028,607 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 135,992 | 230 | 31,316,238 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 71,121 | 310 | 22,046,088 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 15,205 | 321 | 4,877,764 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 87,494 | 321 | 28,068,075 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 449,463 | 321 | 144,187,730 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 757,045 | 323 | 244,321,133 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 136,094 | 323 | 43,952,918 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 35,877 | 330 | 11,839,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 33,882 | 330 | 11,181,060 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 10,000 | 330 | 3,300,000 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 8,550 | 330 | 2,821,500 | Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 976 | 137 | 133,527 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 25,000 | 243 | 6,083,750 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 25,000 | 226 | 5,643,500 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 2,046 | 330 | 675,180 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 13,000 | 245 | 3,186,820 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 29,937 | 138 | 4,126,815 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 8,828 | 330 | 2,913,240 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 5,000 | 330 | 1,650,000 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 63,065 | 137 | 8,627,923 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 38,688 | 330 | 12,767,040 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 19,037 | 330 | 6,282,210 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 10,342 | 330 | 3,412,860 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,696 | 161 | 1,238,363 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,100 | 138 | 981,291 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,312 | 218 | 2,248,325 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 6,562 | 198 | 1,301,638 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 3,281 | 230 | 755,549 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,158 | 330 | 2,362,140 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 14,009 | 330 | 4,622,970 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 25,100 | 143 | 3,582,774 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 73,250 | 218 | 15,970,698 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 66,900 | 198 | 13,270,284 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 70,000 | 230 | 16,119,600 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 231,992 | 321 | 74,423,034 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 11,578 | 323 | 3,736,568 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 47,817 | 327 | 15,639,984 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 15,855 | 330 | 5,232,150 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 9,412 | 330 | 3,105,960 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 13,977 | 330 | 4,612,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 161,850 | 198 | 32,104,566 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 616,703 | 314 | 193,644,742 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,025 | 330 | 2,648,250 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,372,441 | 330 | 452,905,530 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 683 | 330 | 225,390 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 32,500 | 330 | 10,725,000 | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 16,250 | 314 | 5,102,500 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 19,893 | 323 | 6,420,068 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 25,000 | 235 | 5,886,000 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 164 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 7,696 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2023-09-29 | A | 4,496 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 1,744 | 174 | 303,055 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 3,256 | 173 | 563,158 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-10-09 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,245 | 180 | 404,280 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 808 | 179 | 144,551 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 265 | 177 | 46,942 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 401 | 176 | 70,452 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 5,000 | 132 | 658,200 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-11-08 | D | 1,281 | 174 | 223,035 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 99 | 204 | 20,214 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 3,969 | 203 | 804,675 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,116 | 202 | 426,861 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 1,565 | 200 | 313,172 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 10,000 | 132 | 1,316,400 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2023-12-08 | D | 2,251 | 204 | 458,754 | Common | Form 4 ↗ |
| Bill Meury | Director | 2023-12-28 | D | 8,694 | 316 | 2,749,912 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2023-12-28 | D | 3,828 | 316 | 1,210,796 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 9,696 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 5,304 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 15,000 | 317 | 4,752,150 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 9,696 | 112 | 1,085,661 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | A | 5,304 | 132 | 698,219 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-01-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 818 | 317 | 258,946 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 4,182 | 316 | 1,321,721 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 5,000 | 112 | 559,850 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-09 | D | 1,046 | 317 | 331,728 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-09 | D | 1,011 | 317 | 320,629 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-09 | D | 804 | 317 | 254,981 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-02-13 | A | 15,855 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-02-13 | A | 10,306 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-02-13 | A | 38,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-02-13 | D | 278 | 318 | 88,404 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 27,510 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 4,008 | 100 | 399,678 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | A | 27,510 | 7 | 199,998 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-23 | D | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-02-29 | A | 47,378 | 315 | 14,932,598 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-01 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | A | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-04 | D | 30,304 | 0 | 0 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 1,791 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 3,209 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 100 | 319 | 31,896 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | D | 4,900 | 318 | 1,559,817 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 1,791 | 112 | 200,538 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 3,209 | 132 | 422,433 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-08 | A | 2,500 | 5 | 13,625 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 17,350 | 143 | 2,476,539 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 37,813 | 218 | 8,244,368 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 12,837 | 198 | 2,546,347 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 50,000 | 230 | 11,514,000 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,362 | 321 | 2,040,930 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 4,677 | 325 | 1,517,920 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 6,487 | 330 | 2,140,710 | Common | Form 4 ↗ |
| Stephen Brannan | Chief Medical Officer | 2024-03-18 | D | 36,117 | 330 | 11,918,610 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 22,800 | 143 | 3,254,472 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 146,900 | 218 | 32,028,607 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 135,992 | 230 | 31,316,238 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 71,121 | 310 | 22,046,088 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 15,205 | 321 | 4,877,764 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 87,494 | 321 | 28,068,075 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 449,463 | 321 | 144,187,730 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 757,045 | 323 | 244,321,133 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 136,094 | 323 | 43,952,918 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 35,877 | 330 | 11,839,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 33,882 | 330 | 11,181,060 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 10,000 | 330 | 3,300,000 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 8,550 | 330 | 2,821,500 | Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 976 | 137 | 133,527 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 25,000 | 243 | 6,083,750 | Derivative, Class A Common | Form 4 ↗ |
| Christopher J. Coughlin | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 25,000 | 226 | 5,643,500 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 2,046 | 330 | 675,180 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 13,000 | 245 | 3,186,820 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 29,937 | 138 | 4,126,815 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 8,828 | 330 | 2,913,240 | Common | Form 4 ↗ |
| William P. Kane Jr | Chief Commercial Officer | 2024-03-18 | D | 5,000 | 330 | 1,650,000 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 63,065 | 137 | 8,627,923 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 38,688 | 330 | 12,767,040 | Derivative, Class A Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 19,037 | 330 | 6,282,210 | Common | Form 4 ↗ |
| Bill Meury | Director | 2024-03-18 | D | 10,342 | 330 | 3,412,860 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,696 | 161 | 1,238,363 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,100 | 138 | 981,291 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,312 | 218 | 2,248,325 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 6,562 | 198 | 1,301,638 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 3,281 | 230 | 755,549 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 10,306 | 330 | 3,400,980 | Derivative, Class A Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 7,158 | 330 | 2,362,140 | Common | Form 4 ↗ |
| Jason Parker Brown | Chief Financial Officer | 2024-03-18 | D | 14,009 | 330 | 4,622,970 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 25,100 | 143 | 3,582,774 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 73,250 | 218 | 15,970,698 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 66,900 | 198 | 13,270,284 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 70,000 | 230 | 16,119,600 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 231,992 | 321 | 74,423,034 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 11,578 | 323 | 3,736,568 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 47,817 | 327 | 15,639,984 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 15,855 | 330 | 5,232,150 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 9,412 | 330 | 3,105,960 | Common | Form 4 ↗ |
| Andrew Miller | President of R&D | 2024-03-18 | D | 13,977 | 330 | 4,612,410 | Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 161,850 | 198 | 32,104,566 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 616,703 | 314 | 193,644,742 | Derivative, Class A Common | Form 4 ↗ |
| Steven Paul | Director | 2024-03-18 | D | 30,304 | 330 | 10,000,320 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 8,025 | 330 | 2,648,250 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 1,372,441 | 330 | 452,905,530 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 683 | 330 | 225,390 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| James Healy | Director | 2024-03-18 | D | 32,500 | 330 | 10,725,000 | Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 16,250 | 314 | 5,102,500 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 19,893 | 323 | 6,420,068 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey M. Jonas | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Laurie Olson | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 12,500 | 232 | 2,905,125 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 1,904 | 92 | 175,739 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 5,000 | 227 | 1,135,200 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 8,500 | 202 | 1,716,915 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 25,000 | 235 | 5,886,000 | Derivative, Class A Common | Form 4 ↗ |
| David E. Wheadon | Director | 2024-03-18 | D | 990 | 330 | 326,700 | Common | Form 4 ↗ |
Sources (207 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Steven Paul. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 11,224,103. View filing ↗
- Section 01, Andrew Miller. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 5,774,890. View filing ↗
- Section 01, Stephen Brannan. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 4,413,379. View filing ↗
- Section 01, Troy Ignelzi. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 4,006,465. View filing ↗
- Section 01, Charmaine Lykins. DEF 14A, filed 2023-04-27. Section “Executive Compensation”. As printed: 759,650. View filing ↗
- Section 03, Troy Ignelzi OPTION. DEF 14A, filed 2023-04-27. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Stephen Brannan OPTION. DEF 14A, filed 2023-04-27. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Miller OPTION. DEF 14A, filed 2023-04-27. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Paul OPTION. DEF 14A, filed 2023-04-27. Section “Grants of Plan-Based Awards for Fiscal Year 2022” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2023-04-27. Section “CEO Pay Ratio”. As printed: 27 : 1. View filing ↗
- Section 08, Christopher J. Coughlin. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 373,145. View filing ↗
- Section 08, Laurie Olson. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 345,104. View filing ↗
- Section 08, Atul Pande, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 344,604. View filing ↗
- Section 08, James Healy, M.D., Ph.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 336,104. View filing ↗
- Section 08, Denice Torres. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 333,354. View filing ↗
- Section 08, David Wheadon, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 331,104. View filing ↗
- Section 08, Jeffrey Jonas, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 326,604. View filing ↗
- Section 08, Steven Paul, M.D. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Bill Meury. DEF 14A, filed 2023-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jason Parker Brown 2023-09-29. Form 4, filed 2023-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2023-09-29. Form 4, filed 2023-10-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-10-09. Form 4, filed 2023-10-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-11-08. Form 4, filed 2023-11-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2023-12-08. Form 4, filed 2023-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2023-12-28. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2023-12-28. Form 4, filed 2023-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-01-08. Form 4, filed 2024-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-08. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-09. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-02-09. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-09. Form 4, filed 2024-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-02-13. Form 4, filed 2024-02-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-23. Form 4, filed 2024-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-23. Form 4, filed 2024-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-23. Form 4, filed 2024-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-23. Form 4, filed 2024-02-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-02-29. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-01. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-01. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-01. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-01. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-04. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-04. Form 4, filed 2024-03-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-08. Form 4, filed 2024-03-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen Brannan 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher J. Coughlin 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Olson 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Olson 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Olson 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Olson 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William P. Kane Jr 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bill Meury 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Parker Brown 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Miller 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Paul 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Healy 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey M. Jonas 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Laurie Olson 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Atul Pande 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David E. Wheadon 2024-03-18. Form 4, filed 2024-03-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-21. Item 5.07 · say-on-pay result. As reported: 65.16% (votes for as printed: 20,307,726). View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-21. Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 21,124,063). View filing ↗
- Section 06, 2020 vote. Form 8-K, filed 2020-06-17. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 401,292 + equity 0 + all other 0 = 401,292, summed across the director compensation table rows.
- TG Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. View filing ↗
- Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
- Biohaven Pharmaceutical Holding Company Ltd., Section 10b CEO total. DEF 14A, filed 2026-03-13. CEO total compensation as printed in Biohaven Pharmaceutical Holding Company Ltd.'s own proxy. As printed: 13,500,438. View filing ↗
- Mirati Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-06. CEO total compensation as printed in Mirati Therapeutics, Inc.'s own proxy. As printed: 11,937,371. View filing ↗
- Cerevel Therapeutics Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. View filing ↗
- Karuna Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2023-04-27. CEO total compensation as printed in Karuna Therapeutics's own proxy. As printed: 11,224,103. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Axsome Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. View filing ↗
- Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Sage Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Sage Therapeutics, Inc.'s own proxy. As printed: 7,112,589. View filing ↗
- Arvinas, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas, Inc.'s own proxy. As printed: 6,534,127. View filing ↗
- Allakos Inc., Section 10b CEO total. DEF 14A, filed 2024-04-23. CEO total compensation as printed in Allakos Inc.'s own proxy. As printed: 6,299,426. View filing ↗
- Prothena Corporation plc, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Prothena Corporation plc's own proxy. As printed: 5,896,045. View filing ↗
- Denali Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. View filing ↗
- Kodiak Sciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences Inc.'s own proxy. As printed: 2,499,221. View filing ↗
- Alector, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Alector, Inc.'s own proxy. As printed: 1,995,018. View filing ↗
- Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocity. DEF 14A. Cerevel Therapeutics Holdings, Inc. names Karuna Therapeutics in its own disclosed peer group (read from its most recent proxy). View filing ↗